Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
Stock Information for Summit Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.